ArticleMikrochimica acta2026
A robust boronic acid-integrated olefin-linked covalent organic framework for high-performance enrichment of glycopeptides and determination in laryngeal cancer serum.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A robust boronic acid-integrated olefin-linked covalent organic framework (BACOF) was synthesized via a straightforward one-step Knoevenagel condensation. The material combines exceptional structural stability, high surface area, inherent boronic acid affinity, and enhanced hydrophilicity, resulting in outstanding glycopeptide enrichment performance. It exhibits an ultra-low detection limit (0.05 fmol·µL⁻1), high selectivity (HRP: BSA = 1:500), large binding capacity (80 mg·g⁻¹), excellent reusability (7 cycles), and satisfactory recovery (92.5 ± 1.5%). In nano LC-MS/MS analysis of clinical serum samples, BACOF enabled the identification of 250 glycopeptides (from 91 glycoproteins and 212 N-glycosylation sites) in laryngeal cancer patients, and 268 glycopeptides (from 121 glycoproteins and covering 235 N-glycosylation sites) in healthy controls. Label-free quantitative proteomics further revealed that dysregulated glycoproteins were coordinately enriched in immune and vascular-related processes. Five hub glycoproteins, antithrombin-III (SERPINC1), beta-2-glycoprotein 1 (APOH), transthyretin (TTR), alpha-1-acid glycoprotein 1 (ORM1), and vitronectin (VTN), were identified as promising candidate biomarkers for laryngeal cancer. This study establishes olefin-linked COFs as a robust and versatile platform for advanced glycoproteomics and clinical biomarker discovery.
Indexed as
Identifiers
41644746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.